)
The Union Ministry of Health and Family Welfare has proposed changes, to the Drugs Rules, 1945. These changes would let authorities suspend manufacturing licences instantly for medicines that're Not of Standard Quality (NSQ) because they fail certain critical quality parameters. The changes are designed to strengthen drug quality regulation. They also let authorities act quickly against manufacturers who produce medicines. The main goal is to stop the continued manufacture and distribution of drugs that do not meet quality standards. Patient safety and public health remain the priorities. Now the law says that suspending or canceling a drug manufacturing licence must go through a set regulatory process. That process includes sending a show-cause notice to the manufacturer. The new amendments would add a way to suspend licences instantly whenever a specified critical quality failure is found.
What Are The Proposed Changes To The Drugs Rules, 1945?
The proposed amendment seeks to empower the concerned Licensing Authority to suspend a manufacturing licence immediately when a drug is declared NSQ on specified critical quality parameters. This would allow regulators to intervene promptly instead of waiting for the existing suspension or cancellation procedure to run its course. The objective is to prevent manufacturers from continuing to produce and distribute medicines that may pose risks to patients because of serious quality failures. However, the proposal also sets out conditions that manufacturers must fulfil before a suspended licence can be restored.
Manufacturers Will Have To Conduct Root Cause Analysis And Implement CAPA
Under the proposed framework, suspension of a manufacturing licence will continue until the manufacturer identifies the reason behind the quality failure and takes appropriate corrective action. The Ministry has specified two important requirements:
- Root Cause Analysis (RCA): Manufacturers will have to conduct an effective investigation to identify the underlying reason for the drug quality failure.
- Corrective and Preventive Action (CAPA): They will have to implement appropriate corrective and preventive measures to address the identified problem and prevent its recurrence.
The corrective measures must satisfy the concerned Licensing Authority. The suspension will not be revoked simply because the manufacturer has submitted an explanation or promised to improve its processes.
READ | Ayush Minister Calls Upon Citizens To Prioritise Health On Dhanteras
Licensing Authority Must Verify Corrective Measures Before Revocation
The proposed amendment also provides for verification by the Licensing Authority before a suspended manufacturing licence can be restored. According to the Ministry, revocation of the suspension will be permitted only after the necessary corrective and preventive measures have been implemented and duly verified by the concerned authority. This provision is intended to ensure that manufacturers address the actual reasons behind quality failures rather than treating regulatory action as a temporary compliance issue. It also places greater responsibility on pharmaceutical manufacturers to maintain quality standards throughout the manufacturing process.
Why Is The Government Proposing These Amendments?
The proposed changes are aimed at strengthening post-marketing regulatory surveillance and enabling timely action against substandard medicines. Medicines that fail to meet prescribed quality standards can compromise treatment outcomes and may expose patients to avoidable health risks. Depending on the nature of the failure, concerns can include incorrect drug content, contamination, inadequate dissolution or other critical quality defects.
The Ministry said the amendments are expected to strengthen regulatory oversight, prevent the continued manufacture and distribution of substandard medicines and promote greater accountability among manufacturers and marketers. The proposal also seeks to make corrective action an essential condition for restoring manufacturing operations after a serious quality failure.
What Happens Next?
The Ministry has proposed amendments to the Drugs Rules, 1945. The proposal should be distinguished from an amendment that has already come into force. The final regulatory position will depend on the completion of the prescribed rule-making process and notification of the amendment. If implemented, the changes could provide drug regulators with a stronger mechanism to respond to critical quality failures and ensure that manufacturers demonstrate effective corrective action before resuming production. For patients, the broader objective is to strengthen confidence in the quality and safety of medicines available in the country.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.